<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><description>It takes nothing to join the crowd, but it takes everything to stand alone</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 09 May 2021 10:14:57 +0800</pubDate><image><url>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</url><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>祝贺！2021年中国国家药监局(NMPA)“官宣”批准的6款创新药</title><link>https://mp.weixin.qq.com/s/78YFt0r8knYIf-5Ato4GQg</link><description></description><content:encoded><![CDATA[祝贺！2021年中国国家药监局(NMPA)“官宣”批准的6款创新药]]></content:encoded><pubDate>Sun, 09 May 2021 09:00:51 +0800</pubDate></item><item><title>看懂这张图，肺癌药物报销不犯愁！</title><link>https://mp.weixin.qq.com/s/5jGVKeSsHF4uEWZEHuSPWQ</link><description></description><content:encoded><![CDATA[看懂这张图，肺癌药物报销不犯愁！]]></content:encoded><pubDate>Sun, 09 May 2021 09:00:51 +0800</pubDate></item><item><title>ADC药物关键质量属性的考量因素</title><link>https://mp.weixin.qq.com/s/h5_MgWjwtqz6G5ZyeNKUlw</link><description></description><content:encoded><![CDATA[ADC药物关键质量属性的考量因素]]></content:encoded><pubDate>Sun, 09 May 2021 09:00:51 +0800</pubDate></item><item><title>小分子药物的突围之路（上篇）：变构调节剂</title><link>https://mp.weixin.qq.com/s/WqDTgyXHEGq66bRuCSZDYQ</link><description></description><content:encoded><![CDATA[小分子药物的突围之路（上篇）：变构调节剂]]></content:encoded><pubDate>Sun, 09 May 2021 09:00:51 +0800</pubDate></item><item><title>中国、美国、欧洲药典对HPLC方法的规定</title><link>https://mp.weixin.qq.com/s/VvEYfzbUOCQosZLd_OSY2g</link><description></description><content:encoded><![CDATA[中国、美国、欧洲药典对HPLC方法的规定]]></content:encoded><pubDate>Fri, 07 May 2021 20:04:48 +0800</pubDate></item><item><title>NMPA正式适用ICH M9、ICH Q5D生物药指导原则！ICH全套指导原则(中英对照)下载！</title><link>https://mp.weixin.qq.com/s/qhn453TN1wXdmJbtM4CA0Q</link><description></description><content:encoded><![CDATA[NMPA正式适用ICH M9、ICH Q5D生物药指导原则！ICH全套指导原则(中英对照)下载！]]></content:encoded><pubDate>Fri, 07 May 2021 20:04:48 +0800</pubDate></item><item><title>药物经济学在药物研发中的应用</title><link>https://mp.weixin.qq.com/s/3bfp_x7ecIekoPZMKgnZnA</link><description></description><content:encoded><![CDATA[药物经济学在药物研发中的应用]]></content:encoded><pubDate>Fri, 07 May 2021 20:04:48 +0800</pubDate></item><item><title>方法确认和方法验证的区分与31个重要概念</title><link>https://mp.weixin.qq.com/s/3Al6LjZoS0NqDt5aPrUcxA</link><description></description><content:encoded><![CDATA[方法确认和方法验证的区分与31个重要概念]]></content:encoded><pubDate>Fri, 07 May 2021 20:04:48 +0800</pubDate></item><item><title>国产盐酸地芬尼多片与原研制剂的溶出曲线和有关物质比较研究</title><link>https://mp.weixin.qq.com/s/SJ3vLaJqZl81bo-uy3Gh9g</link><description></description><content:encoded><![CDATA[国产盐酸地芬尼多片与原研制剂的溶出曲线和有关物质比较研究]]></content:encoded><pubDate>Thu, 06 May 2021 20:29:27 +0800</pubDate></item><item><title>北京 | 药品上市后变更的沟通交流</title><link>https://mp.weixin.qq.com/s/1XyzvuilGE4DOjGUWYgw4w</link><description></description><content:encoded><![CDATA[北京 | 药品上市后变更的沟通交流]]></content:encoded><pubDate>Thu, 06 May 2021 20:29:27 +0800</pubDate></item><item><title>国产抗生素滴眼液中抑菌剂应用的合理性分析</title><link>https://mp.weixin.qq.com/s/vJA2Hf4wxwpu9XL2eIRJ6A</link><description></description><content:encoded><![CDATA[国产抗生素滴眼液中抑菌剂应用的合理性分析]]></content:encoded><pubDate>Thu, 06 May 2021 20:29:27 +0800</pubDate></item><item><title>最新FDA官网使用指南图解</title><link>https://mp.weixin.qq.com/s/Yra9fuDTGGA92Stsn_Ge7g</link><description></description><content:encoded><![CDATA[最新FDA官网使用指南图解]]></content:encoded><pubDate>Wed, 05 May 2021 18:40:23 +0800</pubDate></item><item><title>生物药的研发与申报详细讲解</title><link>https://mp.weixin.qq.com/s/s9SQ8P28_I5fIAWZqVm6eQ</link><description></description><content:encoded><![CDATA[生物药的研发与申报详细讲解]]></content:encoded><pubDate>Wed, 05 May 2021 18:40:23 +0800</pubDate></item><item><title>《真实世界研究统计分析方法》梳理</title><link>https://mp.weixin.qq.com/s/ddisH422USN1FUy5YaXung</link><description></description><content:encoded><![CDATA[《真实世界研究统计分析方法》梳理]]></content:encoded><pubDate>Wed, 05 May 2021 18:40:23 +0800</pubDate></item><item><title>最全新药研发流程</title><link>https://mp.weixin.qq.com/s/mOV-DAJAA27Y2KguyHDDtQ</link><description></description><content:encoded><![CDATA[最全新药研发流程]]></content:encoded><pubDate>Wed, 05 May 2021 18:40:23 +0800</pubDate></item><item><title>CDE/ ICH指导原则实施情况视频回放</title><link>https://mp.weixin.qq.com/s/RAo8C7wXsLb3ddAGWRdzUQ</link><description></description><content:encoded><![CDATA[CDE/ ICH指导原则实施情况视频回放]]></content:encoded><pubDate>Thu, 29 Apr 2021 20:55:13 +0800</pubDate></item><item><title>抗体药物偶联物治疗恶性肿瘤临床应用专家共识（2020版）</title><link>https://mp.weixin.qq.com/s/hiMp46tIzEpTEapzV3tQ6g</link><description></description><content:encoded><![CDATA[抗体药物偶联物治疗恶性肿瘤临床应用专家共识（2020版）]]></content:encoded><pubDate>Thu, 29 Apr 2021 20:55:13 +0800</pubDate></item><item><title>药品研发中的原辅料相容性实验总结</title><link>https://mp.weixin.qq.com/s/GZRjdOYImPJwIcySSC8MZw</link><description></description><content:encoded><![CDATA[药品研发中的原辅料相容性实验总结]]></content:encoded><pubDate>Wed, 28 Apr 2021 20:01:39 +0800</pubDate></item><item><title>CDE解答化药共性问题-仿制药篇</title><link>https://mp.weixin.qq.com/s/VwOr4-6Uc2z8PSTREXCFEw</link><description></description><content:encoded><![CDATA[CDE解答化药共性问题-仿制药篇]]></content:encoded><pubDate>Wed, 28 Apr 2021 20:01:39 +0800</pubDate></item><item><title>FDA 复杂仿制药的监管现状研究</title><link>https://mp.weixin.qq.com/s/AtcQmBtykkqGCGsl-LZRMw</link><description></description><content:encoded><![CDATA[FDA 复杂仿制药的监管现状研究]]></content:encoded><pubDate>Wed, 28 Apr 2021 20:01:39 +0800</pubDate></item></channel></rss>